Telo Genomics

Telo Genomics Equity

The The Equity of Telo Genomics (TELO.V) as of Oct 25, 2026 is 514,981.00 CAD. In the previous year, The Equity was 590,057.00 CAD — a change of -12.72% (lower).

Equity

514,981.00CAD

YoY

-12.72%

Last updated:

In 2025, Telo Genomics's equity was 514,981.00 CAD, a -12.72% increase from the 590,057.00 CAD equity in the previous year.

The Telo Genomics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-314,017.00 CAD
Jan 1, 2019
-1.04 M CAD
Jan 1, 2020
775,254.00 CAD
Jan 1, 2021
3.69 M CAD
Jan 1, 2022
2.60 M CAD
Jan 1, 2023
2.61 M CAD
Jan 1, 2024
590,057.00 CAD
Jan 1, 2025
514,981.00 CAD
The Telo Genomics Equity history
YEAREquityYoY
514,981.00CAD-12.72%
590,057.00CAD-77.42%
2.61 MCAD+0.37%
2.60 MCAD-29.37%
3.69 MCAD+375.40%
775,254.00CAD-174.20%
-1.04 MCAD+232.74%
-314,017.00CAD-114.10%
2.23 MCAD+293.07%
566,447.00CAD+26.09%
449,236.00CAD-9.79%
497,966.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Telo Genomics Stock analysis

What does Telo Genomics do? Telo Genomics Corp. develops and commercializes predictive technological products for personalized treatment plans, focusing on genomic instability-related diseases. Its lead product, TeloView SMM, is a high-complexity molecular assay for Smoldering Multiple Myeloma patients, using telomere-based analysis to identify high-risk cases needing early treatment and low-risk cases requiring no immediate intervention. The company operates through its wholly owned subsidiary Telo Genomics Holdings Corp., which develops diagnostic and prognostic products for diseases with genomic instability. Telo Genomics Corp. targets physicians and healthcare providers who treat patients with specific conditions requiring personalized therapeutic approaches. The firm's revenue model centers on the commercialization of TeloView SMM, which is available for clinical use. The assay provides critical information to physicians managing Smoldering Multiple Myeloma, enabling tailored treatment decisions. Telo Genomics Holdings Corp. focuses on developing additional diagnostic and prognostic products within the genomic instability disease space, aiming to expand its product portfolio for healthcare providers seeking advanced diagnostic tools. The company's primary customers are medical professionals and healthcare institutions specializing in oncology and hematology, particularly those treating myeloma patients. Telo Genomics Corp. differentiates itself through telomere-based analysis technology, which allows precise risk stratification for Smoldering Multiple Myeloma patients. This approach supports early intervention for high-risk patients while avoiding unnecessary treatments for low-risk cases. The company's product line is designed to address specific clinical needs within the oncology sector, targeting healthcare providers who require accurate diagnostic tools to optimize patient care pathways. The firm's focus on genomic instability diseases positions it within a niche market requiring specialized diagnostic solutions. Telo Genomics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Telo Genomics's Equity

Telo Genomics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Telo Genomics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Telo Genomics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Telo Genomics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Telo Genomics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Telo Genomics stock

The Equity of Telo Genomics is 514,981.00 CAD in 2025.

The Equity of Telo Genomics changed from 590,057.00 CAD to 514,981.00 CAD, representing a -12.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Telo Genomics since 2006 – with annual values, charts, and detailed analysis.

The Equity's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Telo Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Telo Genomics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Telo Genomics